StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$39.10+0.17 (+0.44%)

Close on Nov 20, 2026Market cap $3.78BP/E –Yield –

CRISPR Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

CRISPR Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$371.33M. For fiscal 2025 it was -$345.93M. The highest annual figure on record is $457.27M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$345.93M–
FY2024Dec 31, 2024-$144.68M–
FY2023Dec 31, 2023-$269.85M–
FY2022Dec 31, 2022-$532.93M-216.5%
FY2021Dec 31, 2021$457.27M–
FY2020Dec 31, 2020-$256.72M-613.5%
FY2019Dec 31, 2019$49.99M–
FY2018Dec 31, 2018-$99.01M–
FY2017Dec 31, 2017-$77.91M–
FY2016Dec 31, 2016-$55.88M-195.9%
FY2015Dec 31, 2015$58.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$84.15M–
Q1 FY2026Mar 31, 2026-$109.40M–
Q4 FY2025Dec 31, 2025-$93.07M–
Q3 FY2025Sep 30, 2025-$84.71M–
Q2 FY2025Jun 30, 2025-$114.00M–
Q1 FY2025Mar 31, 2025-$54.15M-149.7%
Q4 FY2024Dec 31, 2024-$50.29M–
Q3 FY2024Sep 30, 2024-$107.13M–
Q2 FY2024Jun 30, 2024-$96.29M–
Q1 FY2024Mar 31, 2024$109.03M+1799.5%
Q4 FY2023Dec 31, 2023-$96.81M–
Q3 FY2023Sep 30, 2023-$41.97M–
Q2 FY2023Jun 30, 2023-$136.80M–
Q1 FY2023Mar 31, 2023$5.74M–
Q4 FY2022Dec 31, 2022-$119.52M–
Q3 FY2022Sep 30, 2022-$111.24M–
Q2 FY2022Jun 30, 2022-$151.59M-119.5%
Q1 FY2022Mar 31, 2022-$150.59M–
Q4 FY2021Dec 31, 2021-$95.22M–
Q3 FY2021Sep 30, 2021-$118.38M–
Q2 FY2021Jun 30, 2021$778.55M–
Q1 FY2021Mar 31, 2021-$107.69M–
Q4 FY2020Dec 31, 2020-$87.45M-3707.7%
Q3 FY2020Sep 30, 2020-$81.22M-162.0%
Q2 FY2020Jun 30, 2020-$32.88M–
Q1 FY2020Mar 31, 2020-$55.17M–
Q4 FY2019Dec 31, 2019$2.42M–
Q3 FY2019Sep 30, 2019$130.96M–
Q2 FY2019Jun 30, 2019-$38.56M–
Q1 FY2019Mar 31, 2019-$44.83M–
Q4 FY2018Dec 31, 2018-$29.37M–
Q3 FY2018Sep 30, 2018-$20.66M–
Q2 FY2018Jun 30, 2018-$25.74M–
Q1 FY2018Mar 31, 2018-$23.24M–
Q4 FY2017Dec 31, 2017-$15.05M–
Q3 FY2017Sep 30, 2017-$18.86M–
Q2 FY2017Jun 30, 2017-$17.30M–
Q1 FY2017Mar 31, 2017-$26.70M–
Q4 FY2016Dec 31, 2016-$17.19M–
Q3 FY2016Sep 30, 2016-$13.79M–

More CRISPR Therapeutics figures

See a number that looks wrong?